BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk...

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

July 19 2018 Cochrane researchers have published research indicating that omega 3 supplements...

DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

MPS advises of need for better awareness of cauda equina red flag symptoms

MPS advises of need for better awareness of cauda equina red flag symptoms

May 9 2018 The Medical Protection Society is advising doctors of a revision to the NICE Clinical...

  • BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    Wednesday, 25 July 2018 14:07
  • Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Effect of omega-3 or other fatty acids on heart disease is negligible finds Cochrane review

    Thursday, 19 July 2018 10:36
  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:22
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:51
  • MPS advises of need for better awareness of cauda equina red flag symptoms

    MPS advises of need for better awareness of cauda equina red flag symptoms

    Wednesday, 09 May 2018 16:01

pills1577x362October 14 2015

The Scottish Medicines Consortium has recommended six products for use in the NHS in Scotland, in its latest Briefing Note. It has also recommended against using one product.

 

 

The items approved by the SMC are as follows:

  • ciclosporin eye drops (Ikervis) is recommended for severe keratitis in adults with dry eye disease, which has not improved despite treatment with tear substitutes;
  • insulin degludec/liraglutide (Xultophy) has been recommended for restricted use in type 2 diabetes in adults in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control; its use should be restricted to those uncontrolled by basal insulin analogues and where GLP-1 receptor agonists can be used as an add-on intensification therapy;
  • abiraterone acetate (Zytiga) has been accepted for use with prednisone or prednisolone for metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic where androgen deprivation therapy has failed but where chemotherapy is not yet clinically indicated; this new recommendation is in addition to its use after a prior chemotherapy regimen;
  • nintedanib (Ofev) is recommended for restricted use in idiopathic pulmonary fibrosis in adults with a predicted forced vital capacity (FVC) less than or equal to 80%
  • radium 223 (Xofigo) is recommended for use in adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases
  • trastuzumab (Herceptin) is recommended for restricted use with certain chemotherapy agents for treating certain carcionomas of the gastro-intestinal tract

The SMC has not recommended everolimus (Afinitor) for hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.

Professor Jonathan Fox, chair of SMC, said: “It is disappointing we were not able to recommend everolimus for the treatment of breast cancer. The patient groups and clinicians who took part in the PACE [Patient and Clinician Engagement] meeting provided a powerful input to the Committee’s deliberations about this medicine.

“However, uncertainty about the clinical benefits of everolimus meant we were unable to accept it. We know this decision will be disappointing to both patients and clinicians as we understand the devastating impact of breast cancer.”

Links:

SMC Briefing Notes

SMC statement

Clinical News

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect them from cancer, the Department of Health and Social Care has announced.
July 20 2018 Doctors are being reminded to ensure that any patient or other records which may be relevant to the UK Infected Blood Inquiry are not destroyed. Earlier this month, the Inquiry’s Chair, Sir...